These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1038 related articles for article (PubMed ID: 27323348)

  • 1. Comparison of treatment invasiveness between upfront debulking surgery versus interval debulking surgery following neoadjuvant chemotherapy for stage III/IV ovarian, tubal, and peritoneal cancers in a phase III randomised trial: Japan Clinical Oncology Group Study JCOG0602.
    Onda T; Satoh T; Saito T; Kasamatsu T; Nakanishi T; Nakamura K; Wakabayashi M; Takehara K; Saito M; Ushijima K; Kobayashi H; Kawana K; Yokota H; Takano M; Takeshima N; Watanabe Y; Yaegashi N; Konishi I; Kamura T; Yoshikawa H;
    Eur J Cancer; 2016 Sep; 64():22-31. PubMed ID: 27323348
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Phase III trial of upfront debulking surgery versus neoadjuvant chemotherapy for stage III/IV ovarian, tubal and peritoneal cancers: Japan Clinical Oncology Group Study JCOG0602.
    Onda T; Matsumoto K; Shibata T; Sato A; Fukuda H; Konishi I; Kamura T; Yoshikawa H;
    Jpn J Clin Oncol; 2008 Jan; 38(1):74-7. PubMed ID: 18258715
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparison of survival between primary debulking surgery and neoadjuvant chemotherapy for stage III/IV ovarian, tubal and peritoneal cancers in phase III randomised trial.
    Onda T; Satoh T; Ogawa G; Saito T; Kasamatsu T; Nakanishi T; Mizutani T; Takehara K; Okamoto A; Ushijima K; Kobayashi H; Kawana K; Yokota H; Takano M; Kanao H; Watanabe Y; Yamamoto K; Yaegashi N; Kamura T; Yoshikawa H;
    Eur J Cancer; 2020 May; 130():114-125. PubMed ID: 32179446
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Feasibility study of neoadjuvant chemotherapy followed by interval debulking surgery for stage III/IV ovarian, tubal, and peritoneal cancers: Japan Clinical Oncology Group Study JCOG0206.
    Onda T; Kobayashi H; Nakanishi T; Hatae M; Iwasaka T; Konishi I; Shibata T; Fukuda H; Kamura T; Yoshikawa H
    Gynecol Oncol; 2009 Apr; 113(1):57-62. PubMed ID: 19181369
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Reduction of cycles of neoadjuvant chemotherapy for advanced epithelial ovarian, fallopian or primary peritoneal cancer (ROCOCO): study protocol for a phase III randomized controlled trial.
    Park SJ; Shim SH; Ji YI; Kwon SH; Lee EJ; Lee M; Chang SJ; Park S; Kim SY; Lee SJ; Kim JW; Roh JW; Lee SH; Song T; Kim HS
    BMC Cancer; 2020 May; 20(1):385. PubMed ID: 32375688
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Re-evaluation of interval debulking surgery in advanced epithelial ovarian cancer].
    Ma Y; Li Y; Cui H; Liang XD; Tang ZJ; Li XP; Zhao Y; Wei LH
    Zhonghua Fu Chan Ke Za Zhi; 2012 May; 47(5):355-60. PubMed ID: 22883524
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Primary debulking surgery vs. neoadjuvant chemotherapy followed by interval debulking surgery for patients with advanced ovarian cancer.
    Bian C; Yao K; Li L; Yi T; Zhao X
    Arch Gynecol Obstet; 2016 Jan; 293(1):163-168. PubMed ID: 26198168
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Phase III randomised clinical trial comparing primary surgery versus neoadjuvant chemotherapy in advanced epithelial ovarian cancer with high tumour load (SCORPION trial): Final analysis of peri-operative outcome.
    Fagotti A; Ferrandina G; Vizzielli G; Fanfani F; Gallotta V; Chiantera V; Costantini B; Margariti PA; Gueli Alletti S; Cosentino F; Tortorella L; Scambia G
    Eur J Cancer; 2016 May; 59():22-33. PubMed ID: 26998845
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Standard first-line chemotherapy with or without nintedanib for advanced ovarian cancer (AGO-OVAR 12): a randomised, double-blind, placebo-controlled phase 3 trial.
    du Bois A; Kristensen G; Ray-Coquard I; Reuss A; Pignata S; Colombo N; Denison U; Vergote I; Del Campo JM; Ottevanger P; Heubner M; Minarik T; Sevin E; de Gregorio N; Bidziński M; Pfisterer J; Malander S; Hilpert F; Mirza MR; Scambia G; Meier W; Nicoletto MO; Bjørge L; Lortholary A; Sailer MO; Merger M; Harter P;
    Lancet Oncol; 2016 Jan; 17(1):78-89. PubMed ID: 26590673
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Study of upfront surgery versus neoadjuvant chemotherapy followed by interval debulking surgery for patients with stage IIIC and IV ovarian cancer, SGOG SUNNY (SOC-2) trial concept.
    Jiang R; Zhu J; Kim JW; Liu J; Kato K; Kim HS; Zhang Y; Zhang P; Zhu T; Aoki D; Yu A; Chen X; Wang X; Zhu D; Zhang W; Jia H; Shi T; Gao W; Yin S; Feng Y; Xiang L; Okamoto A; Zang R
    J Gynecol Oncol; 2020 Sep; 31(5):e86. PubMed ID: 32808504
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The Prognostic Impact of the Pathological Response to Neoadjuvant Dose-Dense Therapy for Ovarian Carcinoma.
    Ebata T; Yunokawa M; Yoshida H; Bun S; Shimoi T; Shimomura A; Kodaira M; Yonemori K; Shimizu C; Fujiwara Y; Kato T; Tamura K
    Int J Gynecol Cancer; 2017 Nov; 27(9):1850-1855. PubMed ID: 29040183
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy and safety of dose-dense paclitaxel plus carboplatin as neoadjuvant chemotherapy for advanced ovarian, fallopian tube or peritoneal cancer.
    Yoshihama T; Nomura H; Iwasa N; Kataoka F; Hashimoto S; Nanki Y; Hirano T; Makabe T; Sakai K; Yamagami W; Hirasawa A; Aoki D
    Jpn J Clin Oncol; 2017 Nov; 47(11):1019-1023. PubMed ID: 28973541
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Management of advanced ovarian cancer in South West Wales - a comparison between primary debulking surgery and primary chemotherapy treatment strategies in an unselected, consecutive patient cohort.
    Drews F; Bertelli G; Lutchman-Singh K
    Cancer Epidemiol; 2017 Aug; 49():85-91. PubMed ID: 28599137
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Primary debulking surgery versus primary neoadjuvant chemotherapy for high grade advanced stage ovarian cancer: comparison of survivals.
    Kobal B; Noventa M; Cvjeticanin B; Barbic M; Meglic L; Herzog M; Bordi G; Vitagliano A; Saccardi C; Skof E
    Radiol Oncol; 2018 Sep; 52(3):307-319. PubMed ID: 30210049
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy and safety of bevacizumab-containing neoadjuvant therapy followed by interval debulking surgery in advanced ovarian cancer: Results from the ANTHALYA trial.
    Rouzier R; Gouy S; Selle F; Lambaudie E; Floquet A; Fourchotte V; Pomel C; Colombo PE; Kalbacher E; Martin-Francoise S; Fauvet R; Follana P; Lesoin A; Lecuru F; Ghazi Y; Dupin J; Chereau E; Zohar S; Cottu P; Joly F
    Eur J Cancer; 2017 Jan; 70():133-142. PubMed ID: 27914243
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Minimal residual disease at primary debulking surgery versus complete tumor resection at interval debulking surgery in advanced epithelial ovarian cancer: A survival analysis.
    Ghirardi V; Moruzzi MC; Bizzarri N; Vargiu V; D'Indinosante M; Garganese G; Pasciuto T; Loverro M; Scambia G; Fagotti A
    Gynecol Oncol; 2020 Apr; 157(1):209-213. PubMed ID: 31952843
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Impact of increased utilization of neoadjuvant chemotherapy on survival in patients with advanced ovarian cancer: experience from a comprehensive cancer center.
    Lee YJ; Chung YS; Lee JY; Nam EJ; Kim SW; Kim S; Kim YT
    J Gynecol Oncol; 2018 Jul; 29(4):e63. PubMed ID: 29770632
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Dose-dense paclitaxel and carboplatin vs. conventional paclitaxel and carboplatin as neoadjuvant chemotherapy for advanced epithelial ovarian, fallopian tube, or primary peritoneal cancer: a retrospective study.
    Shibutani T; Nagao S; Suzuki K; Kaneda M; Yamamoto K; Jimi T; Yano H; Kitai M; Shiozaki T; Matsuoka K; Sudo T; Yamaguchi S
    Int J Clin Oncol; 2020 Mar; 25(3):502-507. PubMed ID: 31677021
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Does neoadjuvant chemotherapy plus cytoreductive surgery improve survival rates in patients with advanced epithelial ovarian cancer compared with cytoreductive surgery alone?
    Solmaz U; Mat E; Dereli ML; Turan V; Peker N; Tosun G; Dogan A; Adiyeke M; Ozdemir A; Gungorduk K; Sanci M; Yildirim Y
    J BUON; 2015; 20(3):847-54. PubMed ID: 26214639
    [TBL] [Abstract][Full Text] [Related]  

  • 20. An analysis of patients with bulky advanced stage ovarian, tubal, and peritoneal carcinoma treated with primary debulking surgery (PDS) during an identical time period as the randomized EORTC-NCIC trial of PDS vs neoadjuvant chemotherapy (NACT).
    Chi DS; Musa F; Dao F; Zivanovic O; Sonoda Y; Leitao MM; Levine DA; Gardner GJ; Abu-Rustum NR; Barakat RR
    Gynecol Oncol; 2012 Jan; 124(1):10-4. PubMed ID: 21917306
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 52.